MICB Overview
Molecule Name
MHC class I polypeptide-related sequence B
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
Background
Acts as a stress-induced self-antigen that is recognized by gamma delta T cells. Ligand for the KLRK1/NKG2D receptor. Binding to KLRK1 leads to cell lysis.
MICB Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Isuventatug | CLN-619 | Phase 1 Clinical | Cullinan MICA Corp | Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Solid tumours | Details |
| FT-536 | FT-536 | Phase 1 Clinical | Fate Therapeutics Inc | Abdominal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Ovarian Neoplasms; Solid tumours | Details |
| FT-836 | FT-836; FT836 | Phase 1 Clinical | Fate Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| DM-919 | DM-919; DM919 | Phase 1 Clinical | D2M Biotherapeutics Inc | Neoplasms; Solid tumours | Details |